hero image

Biogen Idec Announces Conclusion of Arbitration with Genentech

June 16, 2009 Corporate

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Biogen Idec (Nasdaq: BIIB) today announced that an arbitration panel has issued its decision concerning the Company’s collaboration agreement with Genentech, Inc., reaffirming Biogen Idec’s contractual right to fully participate in strategic decisions regarding the development of RITUXAN® (rituximab) and other anti-CD20 antibodies subject to the collaboration.

Specifically, the arbitration panel ruled that a Joint Development Committee (JDC) comprised of three members from each company must unanimously approve a development plan for each specific indication. Based on that finding, the panel also ruled that, absent unanimous approval of the JDC, Genentech may not proceed with further development of 2H7v16 in neuromyelitis optica, 2H7v16 in relapsing-remitting multiple sclerosis (RRMS), or 2H7v114 for oncology. Genentech may continue clinical trials for 2H7 in rheumatoid arthritis and lupus.

“We are pleased the arbitration panel upheld our reading of the contract and affirmed our joint decision-making rights,” said James C. Mullen, Biogen Idec’s President and CEO. “Our partnership with Genentech has been extraordinarily successful, and we look forward to continuing to work with them to help patients in a wide range of diseases.”

The arbitration panel rejected Genentech’s assertion that the November 2003 merger of IDEC Pharmaceuticals Corp. and Biogen Inc. constituted a change of control.

Biogen Idec co-promotes RITUXAN, a treatment for certain B-cell non-Hodgkin’s lymphomas and rheumatoid arthritis, with Genentech in the United States. Biogen Idec entered into the collaboration with Genentech in March 1995. Biogen Idec filed its Demand for Arbitration in June 2006.

About Biogen Idec

Biogen Idec creates new standards of care in therapeutic areas with high unmet medical needs. Founded in 1978, Biogen Idec is a global leader in the discovery, development, manufacturing, and commercialization of innovative therapies. Patients in more than 90 countries benefit from Biogen Idec's significant products that address diseases such as lymphoma, multiple sclerosis and rheumatoid arthritis. For product labeling, press releases and additional information about the company, please visit www.biogenidec.com.




Biogen Idec Media Contact:
Jennifer Neiman, 617-914-6524
Senior Manager, Public Affairs
Biogen Idec Investor Relations Contact:
Eric Hoffman, 617-679-2812
Director, Investor Relations

March 22, 2023
Biogen Provides Update on FDA Advisory Committee Meeting on Tofersen for SOD1-ALS

SOD1-ALS is a rare genetic form of the disease affecting approximately 330 people in the United States CAMBRIDGE, Mass., March 22, 2023 (GLOBE NEWSWIRE) -- Biogen Inc.  (Nasdaq: BIIB) announced today the outcome of the U.S. Food and Drug Administration’s (FDA) Peripheral and Central Nervous System

March 17, 2023
Biogen to Participate in the Stifel 2023 CNS Days

Cambridge, MA, - -  Biogen Inc.   (Nasdaq: BIIB) announced today that Priya Singhal, M.D., M.P.H., Head of Development, will participate in the Stifel 2023 CNS Days. The webcast will be live on Tuesday, March 28, 2023, at 9:15 a.m. ET. To access the live webcast, please visit the Investors section